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Abstract
Objectives To explore trial participants’
understandings of randomisation.
Design In this exploratory study, which used
qualitative research methods, in›depth, semistructured
interviews were carried out with 20 participants from
the CLasP randomised controlled trial. Interviews
were recorded on audio tape and fully transcribed.
Data were analysed by comparing transcripts and
describing emergent themes, using a grounded theory
approach.
Setting The CLasP study comprises three linked
multicentre, pragmatic randomised controlled trials
evaluating the effectiveness and cost effectiveness of
laser therapy, standard surgery, and conservative
management for men with lower urinary tract
symptoms or urinary retention, or both, related to
benign prostatic disease.
Subjects 20 participants in the CLasP study were
interviewed. Sampling was purposeful: men were
included from each of the treatment arms, the two
major centres, and at different points in the trial.
Interventions and outcome measures Interviews
used a checklist of topics to encourage participants to
describe their experiences. Narratives concerning
randomisation were compared to identify common
themes, retaining the context of the discussion to
allow detailed interpretation.
Results Most participants recalled and described
aspects of randomisation, such as the involvement of
chance, comparison, and concealed allocation. Many
found the concept of randomisation difficult, however,
and developed alternative lay explanations to make
sense of their experiences. Inaccurate patient
information and lay interpretations of common trial
terms caused confusion.
Conclusions The provision of clear and accurate
patient information is important, but this alone will
not ensure consistent interpretation of concepts such
as randomisation. Patients may need to discuss the
purposes of randomisation in order to understand
them fully enough to give truly informed consent.
Introduction
The randomised controlled trial is the widely acknowl›
edged design of choice for evaluating medical and sur›
gical treatments.1 2 Though textbooks and reports of
trials in journals focus on issues concerned with
design, methods, and results,1–3 the patient’s perspective
is relatively neglected. Published research has mostly
used questionnaires to examine attitudes towards par›
ticipation in order to improve accrual. Satisfaction with
trial participation is reported by 90›97% of patients.4–6
Those (75›93% of respondents) who said they would
participate in future trials cited altruism5–7 and
personal benefit5 6 8 9 as reasons. Difficulties with travel›
ling and time taken were the only major criticisms.4 6 8
Studies of the public or outpatients indicate that
50›75% would probably participate, with 10›20% defi›
nitely refusing.8 10 11–14 Interpretation of these studies is
difficult because of their reliance on general issues or
hypothetical trials, which do not have direct relevance
to actual participation in real trials. Recent research
has explored how patients’ preferences might be incor›
porated within trials because of their potential
influence on outcome.15–19
Two studies have used qualitative research methods
to explore more detailed perceptions of methods and
terms employed by trials. Roberson et al found that
although respondents were familiar with the term
“experimental study,” two thirds had not heard the
term “clinical trial.”20 Snowdon et al, using in›depth
interviews with parents of critically ill babies, found
that the nature of the trial was often poorly understood
and that there were particular problems with the con›
cept of random allocation, and considerable confusion
and anger relating to parents’ desire for the most suit›
able treatment for their child.21
The existing research record has tended to focus
on hypothetical questions, often in trials of rare condi›
tions, or in Snowdon et al’s case, parents of critically ill
babies.21 The study reported here uses qualitative
research methods to elicit the perspectives of
“ordinary” middle aged and elderly men who require
elective treatment for a common condition and who
have themselves agreed to participate in a pragmatic
randomised controlled trial. This paper focuses on the
ways in which they make sense of the concept that lies
at the heart of the randomised controlled trial: random
allocation.
Patients and methods
The study involved patients eligible for the CLasP
study. This comprises three linked pragmatic ran›
domised controlled trials to evaluate the effectiveness
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of a new technology (laser therapy) compared with
standard surgery (transurethral resection of the
prostate—TURP) for men with acute or chronic
urinary retention; and laser, surgery, and conservative
management (monitoring without active intervention)
for men with lower urinary tract symptoms related to
benign prostatic disease. The aims of this substudy, to
explore the perspectives of patients who agreed or
refused to participate in CLasP, meant that qualitative
research methods were most appropriate.22
Sampling in qualitative research uses non›
probability methods, including “purposeful” sampling,
in which individuals with particular characteristics are
deliberately and systematically selected to explore
emerging analytical themes. In this study, 20 partici›
pants were interviewed; they came from each of the
major clinical centres (11 from A, nine from B), differ›
ent treatment arms (five conservative management,
eight laser therapy, seven TURP), and at different time
points (seven within 3 months and five within 5 months
of randomisation, and eight after receiving treatment).
Men who chose not to participate were also
interviewed (these data will be reported elsewhere).
Data were collected by in›depth interviews carried
out by KF using a semistructured checklist of topics,23–25
covering the same basic issues, including initial
symptoms; recall, understanding, and experience of
recruitment; feelings about participation; experiences
of treatment; and outcome. The aim was to encourage
the men to relate stories about their experiences and to
explore their understandings of what had happened.
Interviews were conducted in the men’s homes and
recorded on audio tape; they lasted from half an hour
to one and a half hours. Each interview was transcribed
by KF verbatim, including descriptions of non›verbal
factors where appropriate. Analysis of the data
proceeded by detailed scrutiny of the transcripts to
identify common themes, which were coded; these
coded segments of text were included in separate word
processing files.26 These files were expanded with new
transcripts and refined, focused, or altered as new
themes emerged. Each individual’s narrative was
examined independently to assess the coherence of
each account. Data collection and analysis continued
concurrently, according to constant comparison meth›
ods of grounded theory, in which data are examined
for similarities and differences within themes, retaining
the context of the discussion and characteristics of the
individuals to aid understanding and allow interpret›
ation and the development of explanations of
findings.27
Treatment in the CLasP study was allocated to each
patient after he had given written informed consent
and completed questionnaires and clinical tests, and
was done by clinical researchers opening consecutive
opaque envelopes. Patients were given an information
sheet that described the study as a randomised
controlled trial and said that it involved comparing
treatments, that one treatment was new (laser therapy),
that there was uncertainty about which treatment was
best, and that allocation would be by chance and by a
clinician opening a sealed envelope.
The results relating to the experience and
understanding of randomisation are presented below
according to the themes which emerged from the
interview data, although space does not permit
detailed descriptions of the context surrounding these
data. Illustrative quotations are provided, selected for
their relevance to the themes and so that the reader
can judge the interpretations of the researchers.
Names have been changed to protect confidentiality.
Results
Understanding randomisation
Almost all the participants were aware of some aspects
of randomisation, and most (14/20) acknowledged the
involvement of chance in the allocation of their
treatment. Often this was transformed into a
description of other (lay) examples of chance, such as a
lottery or lucky dip:
Mr Cooper: But anyway I agreed to have a go at it, a bit of a
lucky dip. She has them in envelopes, which operation you
are going to get, or which method of treatment you are
going to get.
Mr Symonds: He said, oh yes you’ve got a swollen prostate,
you’ll probably have to have an operation but it’s a chance you
might take, which one of them you take, it comes out the hat,
sort of thing you know. It’s out of the hat, you cannot pick.
Around half of the men (11) talked about the study
in terms of it being a comparison between treatments
or an experiment, with the treatment allocation being
unknown until the contents of an envelope were
revealed:
Mr Taylor: She told me that I would either have the laser
treatment or the operation . . . and at the same time
explained that neither she nor the consultant himself knew
which I would get until they chose this famous envelope.
A smaller number (four) were also more explicit
about clinical equipoise—that the doctor did not know
what treatment was best:
Mr Murray: They were unbiased, didn’t give you any impres›
sion that one was better than the other. But the scheme itself
was—I think they wanted to compare, they wanted to do all
three and then make a comparison of what the end results
were.
Explaining treatment allocation
The majority of men developed detailed narratives to
describe and explain their understanding of the
method of treatment allocation. While most were able
to describe aspects of randomisation, such as the
involvement of chance, need for comparison, and con›
cealed allocation, often their narratives contained
other lay explanations of what they thought had
happened or should have happened. Sometimes this
was caused by a clash between experience and
expectation—for example, where they had not seen the
clinician open the envelope as expected:
Mr Mills: When she first explained it, she said you’ll be given
an envelope and you take your pick, apparently, and that
never happened . . . . I never got offered any envelope. I was
just . . . that was the treatment they more or less picked out
for me.
Perhaps the most difficult concept for patients to
comprehend was clinical equipoise. Lay beliefs and
previous experience meant that the men expected cli›
nicians to assign them to treatment based on their spe›
cific symptoms, clinical findings, and age:
Mr Symonds: They still let you do the three card trick and
they just carry it on because from the very first start it is
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written in the pamphlets they give you . . . . You’ve got your
three choices, your TURPs, your—what do you call it [laser
therapy], this one where you’re under management, but I
think it would be even better if they were to tell you that they
prefer, what you’re going to get . . . . I think that would be
better than they let you take your pick when I think, along
the lines, that you know you’re being conned.
Mr Webster: Well [randomisation] was a bit confusing. It was.
They know what’s wrong with us. I thought it would just be
one operation and that was it. If it was an operation, or if
they could have cured it by medication, they would have
decided there and then. The other consultant would have
decided—you know, this lad need medication, or, yes, this lad
needs the operation. KF: Did that surprise you? Mr Webster:
Yes it did actually, it did. I could understand it, but I couldn’t
realise, cope with the idea that whatever the symptoms were,
that was the envelope we were going to get . . . . I just thought
that . . . if it wasn’t too bad, I would get the medication . . . but
it just seems that they’re tossing a coin in the air.
Other common lay views revolved around the
influence of fate, luck, and trust:
Mr Grange: I must say that I was fairly convinced that I was
going to get a laser operation. I don’t feel at all that those
envelopes had anything to do with it.
Mr Cooper: I preferred the one that I got, so I must have
been lucky.
Although the majority of men were able to discuss
randomisation, two patients, both from the same
centre and randomised to laser therapy, did not believe
that their allocation was different from normal clinical
practice. Apart from these two, levels of knowledge
about randomisation and development of alternative
accounts were similar between centres and across
treatment arms.
Meanings of trial terms
Another complicating issue was the lay understanding
of common terms often used by trialists with specific
meanings but which have other meanings outside the
confines of randomised controlled trials, such as “trial”
and “random.” In lay language, the word trial means
something that is tried out, while “at random” relates to
things being done without purpose:
Mr Bowler: She said there was three options which I had
already read about. One was tablets, one was the ordinary
operation, and one was laser. I didn’t really realise that it was
this scheme whereby they were, a trial, you know. Because I
didn’t think the other one is a trial—TURP. It’s longstanding,
isn’t it?
Mr Flint: Well, I suppose there’s a random system. There isn’t
a better way really. I mean, if it was just done randomly like
that without anybody looking to see how certain results had
gone and say “oh well, we’ll take that one for there, we’ll do
this one there.” If it was done randomly like that, then I sup›
pose it’s as good as any.
Discussion
Randomisation and treatment allocation
Most patients were able to describe some aspects of the
concept of randomisation, particularly in terms of the
involvement of chance, with some having a more
detailed understanding of treatment comparison, con›
cealed allocation, and experimental design. In
response to a structured questionnaire about randomi›
sation, most would probably have been shown to
understand the concept in these basic terms.
Qualitative research has shown that individuals
routinely attempt to make sense of events by interpret›
ing them in the context of their existing beliefs.28 29 In
attempting to make sense of their participation in this
trial, these men produced narratives which on the one
hand described their understanding of elements of
randomisation, but on the other hand challenged these
understandings with, for example, accounts about
trusting clinicians to make treatment allocations on the
basis of individual clinical characteristics.
The existence of different accounts about treat›
ment allocation could indicate confusion or distortion,
as has been suggested elsewhere.21 The men in this trial
acknowledged that randomisation was confusing (see
Mr Webster above). Closer examination, however,
shows that these apparently contradictory accounts are
consistent in their own terms. The men’s view that
treatment should be determined by clinical and
personal characteristics (symptoms or age) is rein›
forced by the number and complexity of tests and
questionnaires they complete during the trial. Any
confusion that arises comes from their attempts to
make sense of their experience by trying to piece
together apparently contradictory accounts—not from
a lack of understanding of randomisation.
Information and consent
The terminology used in trials can have different
meanings to participants and trialists. The lay
definition of “random” (see Mr Flint), implies that
treatments are allocated without purpose or control.
Similarly, “trial” means that something is being “tried
and tested” (see Mr Bowler). Mr Bowler is able to
believe that laser therapy is “on trial” but has difficulty
with the idea that the standard operation, TURP, is still
“on trial.” Similar lay definitions have been found else›
where.20 21
Also of importance is consistency between
information given to participants and actual practice.
In the CLasP study, information given to patients indi›
cated that clinicians would open treatment allocation
envelopes in front of patients. In practice, this was not
possible. For some, not seeing the envelopes suggested
that treatment could have been determined by
clinicians. For Mr Symonds, it was the source of distrust
about the study. Patient information needs to be clear
about procedures to avoid such misinterpretation.
Perhaps more important are the implications for
informed consent. Many of these men were struggling
to come to terms with different (sometimes competing)
views about randomisation. Although all had given
written informed consent, it is evident that the majority
did not hold a consistent explanation of the scientific
method underlying the research. Further research is
required to investigate whether these views are found
more widely. It is also not clear what impact such
beliefs may have on outcome, although some patients
were upset by the difficulty of reconciling their views.
Some patients doubted the veracity of the trial.
Conclusion
Although this study confirms the importance of
providing clear and accurate patient information, it
also shows that this in itself is unlikely to ensure
consistent interpretation of concepts such as randomi›
sation by participants. The patient information in this
study was well received and largely accurately recalled,
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but patients still struggled with the concepts underly›
ing the design and sometimes developed coexisting
contradictory accounts. It may be that participants
need to discuss the reasons for particular methods of
trial design (such as randomisation) with researchers
and reflect on these in order to understand them fully
enough to give true informed consent. It is not clear,
however, whether this greater understanding would
lead to higher or lower levels of accrual to trials, but
such an investigation could be linked with research
attempting to incorporate patient preferences into
randomised controlled trials.15 16
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Key messages
+ Most trial participants were able to recall and describe various
aspects of randomisation, including the involvement of chance,
comparison, and concealed allocation
+ The majority found the concept of randomisation difficult to
accept and developed other accounts to make sense of their
experiences
+ The use of terms which have different meanings to lay and
professional audiences (such as trial and random) can cause
confusion among participants
+ Providing clear and accurate patient information is crucial, but to
give truly informed consent patients may also need time to discuss
the purposes of clinical trials and concepts such as randomisation
Fifty years ago
The new NHS: The BMA under fire
To defend the BMA by saying (Aug 21, p 392) that no
organization is perfect but, so long as it acts in good faith and
with courage, it can withstand criticism recalls Mr. Churchill’s
remark about our pre›war Government — that it is a fine thing for
a Prime Minister to be honest but an important thing for a Prime
Minister to be right. Was the BMA right in refusing to allow any
discussion of terms of service during the past six years? It has
been obvious for all of that time that sooner or later the BMA
would offer the services of the profession to the country. When
any of us is going to sell something important his first step is to
get an opinion of what it is worth: satisfactory negotiation is
impossible otherwise. The BMA had a real duty to find out what
value the profession put on its services. The evidence given to the
Spens Committee would pretty certainly have been affected by
such information. It is a doubtful argument to say that a majority
of practitioners have approved the Spens Report. A majority of
practitioners opposed the health service in the second plebiscite,
but the minority view was adopted then. Anyhow, if the BMA had
put discussion of terms on divisional agendas years ago it would
have been in a far better position to appreciate the difficulties of
what it regards as a minority now, instead of spending six years
on principles, of which it evolved seven, or slightly more than one
principle per annum. I challenge any reader to write down at
once those principles (if he remembers them), to reflect on how
many have proved essential, and to say that they justify six years
of planning committees and executive, divisional, representative,
and council meetings. So far as the health service goes no other
result emerged. W A Bourne, Sussex.
(Letter, 4 September 1948, p 499. See also editorial by Gordon
Macpherson, 3 January 1998, p 6.)
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